Cited by 186Protein Degradation and InhibitorsChemical Synthesis and AnalysisUbiquitin and proteasome pathways

Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function

Open access
Luo, Mai, Spradlin, Jessica N., Boike, Lydia, Tong, Bingqi, Brittain, Scott M., McKenna, Jeffrey M., Tallarico, John A., Schirle, Markus +2 more·2021·Cell Chemical Biology

Abstract

The translation of functionally active natural products into fully synthetic small-molecule mimetics has remained an important process in medicinal chemistry. We recently discovered that the terpene natural product nimbolide can be utilized as a covalent recruiter of the E3 ubiquitin ligase RNF114 for use in targeted protein degradation-a powerful therapeutic modality within modern-day drug discovery. Using activity-based protein profiling-enabled covalent ligand-screening approaches, here we report the discovery of fully synthetic RNF114-based recruiter molecules that can also be exploited for PROTAC applications, and demonstrate their utility in degrading therapeutically relevant targets, such as BRD4 and BCR-ABL, in cells. The identification of simple and easily manipulated drug-like scaffolds that can mimic the function of a complex natural product is beneficial in further expanding the toolbox of E3 ligase recruiters, an area of great importance in drug discovery and chemical biology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2021.01.005

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Covalent drug discovery platforms have facilitated expansion of targeted protein degradation by enabling discovery of covalent recruiters against E3 ubiquitin ligases.

    “Covalent drug discovery platforms have facilitated the expansion of targeted protein degradation approaches by enabling the discovery of covalent recruiters against E3 ubiquitin ligases14,187–193.”

    From Advances in covalent drug discovery (2022) · cites this paper as [188]

  • Since 2019, covalent recruiters have been used to validate a large proportion of E3 ligases harnessed for targeted protein degradation, including RNF114, RNF4, DCAF16, DCAF11, KEAP1 and FEM1B.

    “Since 2019, covalent recruiters have been used to validate a large proportion of the E3 ligases that have been harnessed for targeted protein degradation, including RING finger protein 114 (RNF114), RNF4, DDB1 and CUL4-associated factor 16 (DCAF16), DCAF11, KEAP1 and, most recently, fem-1 homologue B (FEM1B)187–193.”

    From Advances in covalent drug discovery (2022) · cites this paper as [188]

  • This enabled design of RNF114-based degraders, expanding to other chemotypes.

    “This enabled the design of RNF114-based degraders, also expanding to other chemotypes.84,85”
  • Additional generic E3 ligases (RNF4, RNF114, KEAP1, FEM1B) have been shown to be exploitable by PROTACs using small-molecule covalent tools to degrade BRD4.

    “a few additional ‘generic’ E3 ligases have been shown to be exploitable by PROTACs, using small-molecule covalent tools that specifically recruit the ligases to degrade the prototypical TPD substrate, BRD4; these ligases include ring finger protein 4 (RNF4)132, RNF114 (refs133–135), KEAP1 (refs136,137) and most recently, fem-1 homologue B (FEM1B)138.”

    From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [134]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Xu T, Park SK, Venable JD, Wohlschlegel JA, Diedrich JK, Cociorva D, Lu B, Liao L, Hewel J, Han X, (2015b). ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteomics 129, 16– 24. 26171723 PMC4630125

Cited by

Sorted by citations

Authors
Luo, M., Spradlin, J. N., Boike, L., Tong, B., Brittain, S. M., McKenna, J. M., Tallarico, J. A., Schirle, M., Maimone, T. J., & Nomura, D. K.
Affiliations
  • University of California, Berkeley (US)
  • Innovative Genomics Institute (US)
Corresponding author
  • Maimone, Thomas J.
  • Nomura, Daniel K.
Venue
Cell Chemical Biology
Publisher
Elsevier BV
Published
2021-04
Volume
28
Issue
4
Pages
559-566.e15
ISSN
  • 2451-9448 (ISSN-L)
  • 2451-9456
OpenAlex
W3123549562
Cited by
186
References
26
Citations by year
2026: 29 · 2025: 34 · 2024: 50 · 2023: 27 · 2022: 34 · 2021: 12
FWCI
9.88
Type
journal article
Language
en
Open access
Locations
  • Cell chemical biology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Mark Foundation For Cancer Research
  • National Cancer Institute
  • Novartis Institutes for BioMedical Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
RNF114, targeted protein degradation, PROTACs, nimbolide, covalent ligands, BRD4 degradation, activity-based protein profiling, chemoproteomics
MeSH terms
Biological Products, Humans, Molecular Structure, Proteomics, Ubiquitin-Protein Ligases, Ubiquitination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review